

# PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

## PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT AND  
THE WRITTEN OPINION OF THE INTERNATIONAL  
SEARCHING AUTHORITY, OR THE DECLARATION

To:

ALFHARMA APS  
Dalslandsgade 11  
DK-2300 Copenhagen B  
DENMARK

(PCT Rule 44.1)

Date of mailing  
(day/month/year)

18/08/2004

Applicant's or agent's file reference

2003-100 PC

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/DK2004/000242

International filing date  
(day/month/year)

02/04/2004

Applicant

ALFHARMA APS

1. ☒ The applicant is hereby notified that the international search report and the written opinion of the International Searching Authority have been established and are transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes  
1211 Geneva 20, Switzerland, Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

- ☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.  
☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

#### 4. Reminders

Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within 18 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Josef Ullrich

**CLAIMS**


1. A method for preparing a steroidal carbothioic acid or a salt thereof, said method comprises:
- A) reacting a steroidal carboxylic acid or a salt thereof with a coupling agent selected from the
- 5 group consisting of carbodiimide derivatives represented by the following formula:
- $$R_5-N=C=N-R_6$$
- wherein  $R_5$  and  $R_6$  are the same or different, and each represent an aliphatic, heteroaliphatic, carbocyclic or a heterocyclic group [all said groups are optionally substituted]; alone or in conjunction with a coupling enhancer; and
- 10 B) reacting the product of step A) with a nucleophilic agent comprising a sulfur atom.

2. A method according to claim 1 in which the coupling agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).

- 15 3. A method according to claim 2, in which the coupling agent is the hydrochloride salt of EDC.


4. A method according to any of the preceding claims, in which the coupling enhancer is selected from the group consisting of:

- A) a heterocyclic ring containing one or two nitrogen atoms, said ring being optionally
- 20 substituted; such as a compound of formula (D) or formula (E),



- wherein  $R_{11}$  and  $R_{12}$  can be the same or different, and each represent a hydrogen atom or a
- 25 cyano group;  $R_{13}$  represent a hydrogen atom or an alkyl group; and  $R_{14}$  represent a hydrogen atom or a salt of a sulfonic acid such as sodium sulfonate  $[-S(=O)(=O)-O^- Na^+]$ ; and
- B) an unsaturated 5-6 membered heterocyclic ring fused to an aromatic- or heteroaromatic ring in which the said heterocyclic ring contains three nitrogen atoms, said rings being optionally substituted, such as a compound of formula (F) or formula (G),

30



$X = H, F, Cl, Br$  and  $Y = CH, N, O, S$

AMENDED SHEET

6.Dec. 2004 18:52

Nr. 0454 S. 8

2003-100 PC

preferably 6-chloro-hydroxybenzotriazole (6-Cl-HOBT), 7-aza-hydroxybenzotriazole (HOAT), or 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (Obht-OH).

5. A method according to any of the preceding claims, where the nucleophilic agent comprising a sulfur atom is selected from the group comprising:

- compounds of formula  $[M]^+ [SH]^-$  wherein M is a metal such as Li, Na or K; or  $[M]^{2+} [S]^{2-}$  wherein M is a metal such as Ca or Mg, the said sulfide salts being optionally hydrated (such as sodium hydrosulfide hydrate); and


10 - an *in situ* generated sulfide salt or a hydrated sulfide salt.

6. The method of any of the preceding claims, wherein the nucleophilic agent is dissolved in a suitable solvent prior to addition to the reaction mixture, or wherein the nucleophilic agent is added in the form of a solid salt or as a solution of the salt in water and/or an organic solvent or

15 a combination thereof.

7. A method according to any of the preceding claims for preparing a steroidal carbothioic acid of formula (IV) or a salt thereof

20



Wherein the symbol  $\text{---}$  in the 1,2-position represent a single or a carbon-carbon double bond;


- 25  $R_1$  represents a hydrogen atom, a hydroxy- or an alkoxy group (such as an optionally substituted  $C_{1-6}$  alkoxy) in the  $\alpha$ -configuration, a group  $-O-C(=O)-R_6$ , where  $R_6$  is an alkyl group (such as optionally substituted  $C_{1-6}$  alkyl) or an optionally substituted 5-6 membered heterocyclic ring containing either oxygen, nitrogen or sulfur as ring hetero atom (such as a furanyl-, pyrrolyl- or a thiophenyl group);
- 30  $R_2$  represents a hydrogen atom, a hydroxy group, an alkoxy group (such as an optionally substituted  $C_{1-6}$  alkoxy) in the  $\alpha$ -configuration, an alkyl group (such as an optionally substituted  $C_{1-6}$  alkyl) which may be in either the  $\alpha$ - or  $\beta$ -configuration, an alkylene group (such as an optionally substituted  $C_{1-6}$  alkylene having the two free valencies on the same carbon atom,

6. Dec. 2004 18:52


Nr. 0454 S. 9

2003-100 PC

preferably methylene) [the alkylene group bound to the steroid nucleus via a double bond] or  $R_1$  and  $R_2$  together represent



- 5 where  $R_7$  and  $R_8$  are the same or different and each represent a hydrogen atom or an alkyl group (such as an optionally substituted  $C_{1-6}$  alkyl);
- $R_3$  represent a hydrogen atom, hydroxy- or a protected hydroxy group in either the  $\alpha$ - or  $\beta$ -configuration or an oxo group (in which case the bond between  $R_3$  and the steroid nucleus is a double bond);
- 10  $R_4$  represents a hydrogen- or a halogen atom or  $R_3$  and  $R_4$  together represent a carbon-carbon bond or an epoxy group in the  $\beta$ -configuration; and
- $R_5$  represents a hydrogen- or a halogen atom in either the  $\alpha$ - or  $\beta$ -configuration;
- $R_6$  represents a hydrogen atom or  $R_6$  represent a metal ion [eg. the moiety  $-S-R_6$  represents a group of the formula  $[-S]^- [M]^+$  wherein M is a metal such as Li, Na or K]; the method
- 15 comprising;
- A) reacting a steroidal carboxylic acid of formula (II) or a salt thereof




- 20 in which the substituents of formula (II) have the above defined meaning with a coupling agent alone or in conjunction with an coupling enhancer, followed by the reaction with a nucleophilic agent comprising a sulfur atom; and optionally
- B) reacting the product from step A) with an acid.
- 25 8. The method of any of the preceding claims, wherein i)
- the coupling agent is added before the coupling enhancer, or
  - the coupling enhancer is added before the coupling agent, and/or wherein ii)
  - the steroidal carboxylic acid is added to a mixture of the coupling agent and the coupling enhancer, or wherein
- 30 - a mixture of the coupling agent and the coupling enhancer is added to a steroidal carboxylic acid, or wherein

- the steroidal carboxylic acid is added to a mixture of the coupling agent and the coupling enhancer in a polar aprotic solvent, preferably DMF or DMA, at elevated temperature.


- 5 9. A method for preparing a steroidal carbothioate (i.e. the ester of the steroidal carbothioic acid), or a salt thereof, the method comprising:  
reacting a steroidal carbothioic acid or a salt thereof, which is prepared as defined in any of the preceding claims, with an electrophilic agent.
- 10 10. A method according to claim 9, in which the electrophilic agent is selected from the group consisting of:  $C_{1-6}$  di- or trihaloalkanes, preferably a trihalo- or a dihalomethane, such as chlorobromomethane or bromofluoromethane.
11. A method according to claim 9 or 10 for preparing a steroidal carbothioate of formula (I)

15



wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_5$  are defined as in claim 7; and  
 $R_{10}$  represents a  $C_{1-6}$  haloalkyl or an optionally substituted heterocyclic ring, the method comprising:

- 20 A) reacting a steroidal carboxylic acid of formula (II)




with a coupling agent and a coupling enhancer [such as a compound of formula (D) or formula (E)]

25

6 Dec. 2004 18:52

Nr. 0454 S. 11

2003-100 PC



wherein  $R_{11}$  and  $R_{12}$  independently represent a hydrogen atom or a cyano group (C=N);


$R_{13}$  represent a hydrogen atom or an alkyl group; and

5  $R_{14}$  represent a hydrogen atom or a moiety of a sulfonic acid, such as sodium sulfonate (eg. the group  $-S(=O)(=O)-O Na^+$ );

B) reacting the product from step A) with a nucleophilic agent comprising sulfur; and

C) reacting the product from step B) with an electrophilic agent [such as a  $C_{1-6}$  di- or trihaloalkane, preferably a trihalo- or a dihalomethane such as chlorofluoromethane or

10 bromofluoromethane] or a compound of the following formula;



wherein  $X=H, F, Cl, Br$  and;  $Y=CH_2, NH, O, S$ , preferably  $X=Cl$  and  $Y=O$ .

15

12. The method of claim 11, wherein the coupling enhancer is selected from the group consisting of: NMI (N-methylimidazole); DCI (4,5-dicyanimidazole); NHS (N-hydroxysuccinimide); and sulfo-NHS (N-hydroxysulfosuccinimide).

20 13. The method of any of the claims 11-12, wherein step C) constitutes the *in situ* reaction of the product from step B) with bromofluoromethane to form a compound of formula (I) wherein  $R_{10}$  is a fluoromethyl group, such as fluticasone propionate.

14. The method according to any of the preceding claims, in which

- 25
- at least two subsequent steps are performed *in situ*, i.e. without any change or removal of solvents, or isolation of the individual intermediates; and/or
  - the method is conducted as a continuous method; and/or
  - step A), B) and optionally step C) are conducted as a one-pot synthesis without solvent changes and/or are performed at room or elevated temperature.

30

15. The method of any of the claims 9-14, wherein an androstane  $17\beta$ -carboxylic acid is converted to an androstane  $17\beta$ -carbothioate.

16. The method of any of the preceding claims, wherein step B) provides an alkali metal salt of


35 the thioic acid, such as a compound of formula (IV), in which the moiety  $-S-R_5$  represent a

6. Dec. 2004 18:52

Nr. 0454 S. 12


2003-100 PC

group of the formula  $[-S]^{-}[M]^{+}$  wherein M is a metal such as Li, Na or K e.g.  $-S^{-}Na^{+}$ , and the other substituents have the same meaning as defined in claim 7.





5

17. A compound of the formula (III) and salts and solvates thereof



10 wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_5$  are defined as in claim 7; and

Z represent the structural moiety resulting from the reaction between the steroidal carboxylic acid of formula (II) and a coupling agent (preferably EDC), followed by a coupling enhancer selected from the group consisting of the compounds of formulas (D); (E); (F); and (G):



15

wherein  $R_{11}$  and  $R_{12}$  independently represent a hydrogen atom or a cyano group;  $R_{13}$  represent a hydrogen atom or a methyl group; and  $R_{14}$  represent a hydrogen atom or a moiety of a sulfonic acid, such as sodium sulfonate [ie. the group  $-S(=O)(=O)-O^{-}Na^{+}$ ],


20

6

6.Dec. 2004 18:52

Nr. 0454 S. 13

2003-100 PC



X - H, F, Cl, Br and Y - CH, N, O, S

with the proviso that:

- 5 when the coupling enhancer is a compound of formula (F), X can not represent H when Y represents CH;  
When the coupling enhancer is a compound of formula (D), R11 and R12 can not both represent H when R1 in formula III represents OH; and  
when the coupling enhancer is a compound of formula (E), R14 can not represent H when R1 in  
10 formula III represents H;

and with the further proviso that


succinimidyl-9 $\alpha$ -fluoro-11 $\beta$ ,17 $\alpha$ -dihydroxy-16 $\alpha$ -methyl-3-oxoandrosta-1,4-diene-17 $\beta$ -carboxylate:

- 15 17 $\alpha$ -hydroxy-4-androsten-3-one-17 $\beta$ -carboxylic acid N-hydroxysuccinimide ester;  
N-hydroxysuccinimidyl-9-fluoro-16 $\alpha$ -methyl-11 $\beta$ ,17-dihydroxy-3-oxo-1,4-androstadiene-17 $\beta$ -  
carboxyester;  
N-hydroxysuccinimide ester of dexamethasone-17 $\beta$ -carboxylic acid; and  
1-[(9 $\alpha$ -fluoro-11 $\beta$ -hydroxy-16 $\beta$ -methyl-3-oxo-17 $\alpha$ -propionyloxyandrost-1,4-dien-17 $\beta$ -  
20 yl)carbonyl]imidazole are disclaimed.

18. The compound of claim 17, wherein at least one of R<sub>11</sub> and R<sub>12</sub> is a cyano group (C≡N), and/or R<sub>13</sub> is a hydrogen atom, and/or formula (D) is NMI (N-methylimidazole) or DCI (4,5-dicyano-imidazole), and/or formula (E) is NHS (N-hydroxysuccinimide) or sulfo-NHS (N-hydroxysulfosuccinimide).

**19. The compound having the formula:**






In which the substituents have the same meaning as defined in claim 17, and salts and solvates thereof, with the proviso that R14 can not represent H when R1 represents H.

5

20. A compound of the formula (VI) and salts and solvates thereof



10 wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are defined as in claim 7; and  
R<sub>a</sub> and R<sub>b</sub> are defined as in claim 1;  
with the proviso that 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide-6 $\alpha$ ,9 $\alpha$ -difluoro-11 $\beta$ -hydroxy-16 $\alpha$ ,17 $\alpha$ -isopropylidenedioxy-3-oxo-androsta-1,4-diene-17 $\beta$ -carboxylate is disclaimed.

15 21. A composition comprising a compound as defined in any of claims 17-20.

22. Use of a compound of any of the claims 17-20 as an intermediate in a method for preparing a steroidal carbothioate or a steroidal carbothioic acid, such as in a method for preparing fluticasone propionate.

20

23. Use according to claim 22, in which the method comprises reaction with a nucleophilic agent comprising a sulfur atom and/or comprises reaction with an electrophilic agent.

x


6 Dec. 2004 18:52

Nr.0454 S. 7

2003-100 PC

**CLAIMS**

1. A method for preparing a steroidal carbothioic acid or a salt thereof, said method comprises:  
 A) reacting a steroidal carboxylic acid or a salt thereof with a coupling agent selected from the  
 5 group consisting of carbodiimide derivatives represented by the following formula:




wherein  $R_a$  and  $R_b$  are the same or different, and each represent an aliphatic, heteroaliphatic, carbocyclic or a heterocyclic group [all said groups are optionally substituted];  
 alone or in conjunction with a coupling enhancer; and

- 10 B) reacting the product of step A) with a nucleophilic agent comprising a sulfur atom.
2. A method according to claim 1 in which the coupling agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).
- 15 3. A method according to claim 2, in which the coupling agent is the hydrochloride salt of EDC.


4. A method according to any of the preceding claims, in which the coupling enhancer is selected from the group consisting of:

- A) a heterocyclic ring containing one or two nitrogen atoms, said ring being optionally  
 20 substituted; such as a compound of formula (D) or formula (E),



- wherein  $R_{11}$  and  $R_{12}$  can be the same or different, and each represent a hydrogen atom or a  
 25 cyano group;  $R_{13}$  represent a hydrogen atom or an alkyl group; and  $R_{14}$  represent a hydrogen atom or a salt of a sulfonic acid such as sodium sulfonate  $[-S(=O)(=O)-O^- Na^+]$ ; and  
 B) an unsaturated 5-6 membered heterocyclic ring fused to an aromatic- or heteroaromatic ring  
 in which the said heterocyclic ring contains three nitrogen atoms, said rings being optionally  
 substituted, such as a compound of formula (F) or formula (G),

30



$X = H, F, Cl, Br$  and  $Y = CH, N, O, S$

6 Dec. 2004 18:52


Nr.0454 S. 8

2003-100 PC

preferably 6-chloro-hydroxybenzotriazole (6-Cl-HOBT), 7-aza-hydroxybenzotriazole (HOAT), or 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (Dbht-OH).

- 5 A method according to any of the preceding claims, where the nucleophilic agent comprising a sulfur atom is selected from the group comprising:
- compounds of formula  $[M]^+ [SH]^-$  wherein M is a metal such as Li, Na or K; or  $[M]^{2+} [S]^{2-}$  wherein M is a metal such as Ca or Mg, the said sulfide salts being optionally hydrated (such as sodium hydrosulfide hydrate); and
  - 10 - an *in situ* generated sulfide salt or a hydrated sulfide salt.
6. The method of any of the preceding claims, wherein the nucleophilic agent is dissolved in a suitable solvent prior to addition to the reaction mixture, or wherein the nucleophilic agent is added in the form of a solid salt or as a solution of the salt in water and/or an organic solvent or
- 15 a combination thereof.
7. A method according to any of the preceding claims for preparing a steroidal carbothioic acid of formula (IV) or a salt thereof

20



Wherein the symbol  $\text{---}$  in the 1,2-position represent a single or a carbon-carbon double bond;


- 25  $R_1$  represents a hydrogen atom, a hydroxy- or an alkoxy group (such as an optionally substituted  $C_{1-6}$  alkoxy) in the  $\alpha$ -configuration, a group  $-O-C(=O)-R_6$ , where  $R_6$  is an alkyl group (such as optionally substituted  $C_{1-6}$  alkyl) or an optionally substituted 5-6 membered heterocyclic ring containing either oxygen, nitrogen or sulfur as ring hetero atom (such as a furanyl-, pyrrolyl- or a thiophenyl group);
- 30  $R_2$  represents a hydrogen atom, a hydroxy group, an alkoxy group (such as an optionally substituted  $C_{1-6}$  alkoxy) in the  $\alpha$ -configuration, an alkyl group (such as an optionally substituted  $C_{1-6}$  alkyl) which may be in either the  $\alpha$ - or  $\beta$ -configuration, an alkylene group (such as an optionally substituted  $C_{1-6}$  alkylene having the two free valencies on the same carbon atom,

6.Dec. 2004 18:52


Nr. 0454 S. 9

2003-100 PC

preferably methylene) [the alkylene group bound to the steroid nucleus via a double bond] or  $R_1$  and  $R_2$  together represent



- 5 where  $R_7$  and  $R_8$  are the same or different and each represent a hydrogen atom or an alkyl group (such as an optionally substituted  $C_{1-6}$  alkyl);
- $R_3$  represent a hydrogen atom, hydroxy- or a protected hydroxy group in either the  $\alpha$ - or  $\beta$ -configuration or an oxo group (in which case the bond between  $R_3$  and the steroid nucleus is a double bond);
- 10  $R_4$  represents a hydrogen- or a halogen atom or  $R_3$  and  $R_4$  together represent a carbon-carbon bond or an epoxy group in the  $\beta$ -configuration; and
- $R_5$  represents a hydrogen- or a halogen atom in either the  $\alpha$ - or  $\beta$ -configuration;
- $R_6$  represents a hydrogen atom or  $R_6$  represent a metal ion [eg. the moiety  $-S-R_6$  represents a group of the formula  $[-S]^- [M]^+$  wherein M is a metal such as Li, Na or K]; the method
- 15 comprising;
- A) reacting a steroidal carboxylic acid of formula (II) or a salt thereof



- 20 In which the substituents of formula (II) have the above defined meaning with a coupling agent alone or in conjunction with an coupling enhancer, followed by the reaction with a nucleophilic agent comprising a sulfur atom; and optionally
- B) reacting the product from step A) with an acid.
- 25 B. The method of any of the preceding claims, wherein i)
- the coupling agent is added before the coupling enhancer, or
  - the coupling enhancer is added before the coupling agent, and/or wherein ii)
  - the steroidal carboxylic acid is added to a mixture of the coupling agent and the coupling enhancer, or wherein
- 30 - a mixture of the coupling agent and the coupling enhancer is added to a steroidal carboxylic acid, or wherein

6 Dec. 2004 18:52


Nr. 0454 S. 10

2003-100 PC

- the steroidal carboxylic acid is added to a mixture of the coupling agent and the coupling enhancer in a polar aprotic solvent, preferably DMF or DMA, at elevated temperature.


- 5 9. A method for preparing a steroidal carbothioate (i.e. the ester of the steroidal carbothioic acid), or a salt thereof, the method comprising;  
 reacting a steroidal carbothioic acid or a salt thereof, which is prepared as defined in any of the preceding claims, with an electrophilic agent.
- 10 10. A method according to claim 9, in which the electrophilic agent is selected from the group consisting of:  $C_{1-8}$  di- or trihaloalkanes, preferably a trihalo- or a dihalomethane, such as chlorobromomethane or bromofluoromethane.
11. A method according to claim 9 or 10 for preparing a steroidal carbothioate of formula (I)

15



wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_5$  are defined as in claim 7; and  $R_{10}$  represents a  $C_{1-8}$  haloalkyl or an optionally substituted heterocyclic ring, the method comprising:

- 20 A) reacting a steroidal carboxylic acid of formula (II)




with a coupling agent and a coupling enhancer [such as a compound of formula (D) or formula (E)]

6. Dec. 2004 18:52


Nr. 0454 S. 11

2003-100 PC



wherein  $R_{11}$  and  $R_{12}$  independently represent a hydrogen atom or a cyano group ( $C\equiv N$ );  
 $R_{13}$  represent a hydrogen atom or an alkyl group; and

- 5  $R_{14}$  represent a hydrogen atom or a moiety of a sulfonic acid, such as sodium sulfonate (eg. the group  $-S(=O)(=O)-O Na^+$ );
- B) reacting the product from step A) with a nucleophilic agent comprising sulfur; and
- C) reacting the product from step B) with an electrophilic agent [such as a  $C_{1-6}$  di- or trihaloalkane, preferably a trihalo- or a dihalomethane such as chlorofluoromethane or
- 10 bromofluoromethane] or a compound of the following formula;



wherein  $X=H, F, Cl, Br$  and;  $Y=CH_3, NH, O, S$ , preferably  $X=Cl$  and  $Y=O$ .

- 15 12. The method of claim 11, wherein the coupling enhancer is selected from the group consisting of: NMI (N-methylimidazole); DCI (4,5-dicyanimidazole); NHS (N-hydroxysuccinimide); and sulfo-NHS (N-hydroxysulfosuccinimide).
- 20 13. The method of any of the claims 11-12, wherein step C) constitutes the *in situ* reaction of the product from step B) with bromofluoromethane to form a compound of formula (I) wherein  $R_{10}$  is a fluoromethyl group, such as fluticasone propionate.
14. The method according to any of the preceding claims, in which
- 25 - at least two subsequent steps are performed *in situ*, i.e. without any change or removal of solvents, or isolation of the individual intermediates; and/or
- the method is conducted as a continuous method; and/or
- step A), B) and optionally step C) are conducted as a one-pot synthesis without solvent changes and/or are performed at room or elevated temperature.
- 30 15. The method of any of the claims 9-14, wherein an androstane  $17\beta$ -carboxylic acid is converted to an androstane  $17\beta$ -carbothioate.


16. The method of any of the preceding claims, wherein step B) provides an alkali metal salt of
- 35 the thioic acid, such as a compound of formula (IV), in which the moiety  $-S-R_3$  represent a

6.Dec. 2004 18:52

Nr.0454 S. 12


2003-100 PC

group of the formula  $[-S]^-[M]^+$  wherein M is a metal such as Li, Na or K e.g.  $-S^- Na^+$ , and the other substituents have the same meaning as defined in claim 7.




5

17. A compound of the formula (III) and salts and solvates thereof



10 wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_5$  are defined as in claim 7; and Z represent the structural moiety resulting from the reaction between the steroidal carboxylic acid of formula (II) and a coupling agent (preferably EDC), followed by a coupling enhancer selected from the group consisting of the compounds of formulas (D); (E); (F); and (G):



15


wherein  $R_{11}$  and  $R_{12}$  independently represent a hydrogen atom or a cyano group;  $R_{13}$  represent a hydrogen atom or a methyl group; and  $R_{14}$  represent a hydrogen atom or a moiety of a sulfonic acid, such as sodium sulfonate [ie. the group  $-S(=O)(=O)-O^- Na^+$ ],

20

6.Dec. 2004 18:52

Nr. 0454 S. 13

2003-100 PC



X - H, F, Cl, Br and Y - CH, N, O, S

with the proviso that:

- 5 when the coupling enhancer is a compound of formula (F), X can not represent H when Y represents CH;
- When the coupling enhancer is a compound of formula (D), R<sub>11</sub> and R<sub>12</sub> can not both represent H when R<sub>1</sub> in formula III represents OH; and
- when the coupling enhancer is a compound of formula (E), R<sub>14</sub> can not represent H when R<sub>1</sub> in
- 10 formula III represents H;

and with the further proviso that

succinimidyl-9 $\alpha$ -fluoro-11 $\beta$ ,17 $\alpha$ -dihydroxy-16 $\alpha$ -methyl-3-oxoandrosta-1,4-diene-17 $\beta$ -carboxylate;

- 15 17 $\alpha$ -hydroxy-4-androsten-3-one-17 $\beta$ -carboxylic acid-N-hydroxysuccinimide ester;
- N-hydroxysuccinimidyl-9-fluoro-16 $\alpha$ -methyl-11 $\beta$ ,17-dihydroxy-3-oxo-1,4-androstadiene-17 $\beta$ -carboxyester;
- N-hydroxysuccinimide ester of dexamethasone-17 $\beta$ -carboxylic acid; and
- 1-[(9 $\alpha$ -fluoro-11 $\beta$ -hydroxy-16 $\beta$ -methyl-3-oxo-17 $\alpha$ -propionyloxyandrosta-1,4-dien-17 $\beta$ -yl)carbonyl]imidazole are disclaimed.
- 20

18. The compound of claim 17, wherein at least one of R<sub>11</sub> and R<sub>12</sub> is a cyano group (C $\equiv$ N), and/or R<sub>13</sub> is a hydrogen atom, and/or formula (D) is NMI (N-methylimidazole) or DCI (4,5-dicyanoimidazole), and/or formula (E) is NHS (N-hydroxysuccinimide) or sulfo-NHS (N-hydroxysulfosuccinimide).
- 25


19. The compound having the formula:



6 Dec. 2004 18:53

Nr. 0454 S. 14


2003-100 PC



In which the substituents have the same meaning as defined in claim 17, and salts and solvates thereof, with the proviso that R<sub>14</sub> can not represent H when R<sub>1</sub> represents H.

5

20. A compound of the formula (VI) and salts and solvates thereof



10 wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are defined as in claim 7; and

R<sub>a</sub> and R<sub>b</sub> are defined as in claim 1;

with the proviso that 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide-6 $\alpha$ ,9 $\alpha$ -difluoro-11 $\beta$ -hydroxy-16 $\alpha$ ,17 $\alpha$ -isopropylidenedioxy-3-oxo-androsta-1,4-diene-17 $\beta$ -carboxylate is disclaimed.

15 21. A composition comprising a compound as defined in any of claims 17-20.

22. Use of a compound of any of the claims 17-20 as an intermediate in a method for preparing a steroidal carbothioate or a steroidal carbothioic acid, such as in a method for preparing fluticasone propionate.

20

23. Use according to claim 22, in which the method comprises reaction with a nucleophilic agent comprising a sulfur atom and/or comprises reaction with an electrophilic agent.